2 min read
Taiwan is making significant changes to its pharmaceutical reimbursement system, and global pharma companies should pay close attention.
The country’s National Health Insurance Administration (NHIA) recently introduced pricing reforms aimed at balancing three major priorities: improving access to innovative medicines, maintaining healthcare affordability, and ensuring a stable drug supply.
For pharmaceutical companies operating in Taiwan or planning market entry, these reforms could directly impact pricing strategies, reimbursement timelines, and long-term profitability.
Why Taiwan Is Changing Its Drug Pricing System
Taiwan’s healthcare system has long relied on annual drug price adjustments to manage healthcare spending. However, repeated pricing cuts have raised concerns about product profitability and potential drug shortages.
In response, Taiwan has introduced reforms designed to create a more sustainable pricing framework. According to Taiwan’s NHIA:
- Only 2,343 out of 12,652 reviewed drugs saw price adjustments
- The latest pricing adjustment rate dropped to 65%, the lowest on record
- The savings generated from price adjustments will be reinvested to facilitate the listing and reimbursement of new drugs
This signals a more balanced approach between cost control and pharmaceutical innovation.
Key Changes Pharma Companies Should Watch
1. Lower Frequency of Aggressive Price Cuts
Taiwan is reducing the scale of annual pricing cuts to protect manufacturers from severe reimbursement pressure.
This helps companies maintain pricing stability while reducing concerns around shrinking margins.
2. Stronger Focus on Drug Supply Stability
Taiwan is actively addressing supply disruption risks caused by:
- Rising raw material costs
- Global transportation challenges
- Supply chain disruptions
To reduce shortages, Taiwan introduced measures that protect essential medicines from aggressive pricing cuts.
3. Faster Access for Innovative Drugs
Taiwan is introducing mechanisms that help bring innovative drugs to patients faster through:
- Parallel review mechanisms
- Faster reimbursement listing
- Proactive drug inclusion initiatives
This creates opportunities for innovative drug manufacturers entering Taiwan.
4. Incentives for Domestic Manufacturing
Taiwan is encouraging local pharmaceutical manufacturing by offering pricing advantages for:
- Locally manufactured drugs
- Products using local APIs
- Certain generic and biosimilar products
This reflects Taiwan’s broader push toward healthcare resilience.
5. Greater Focus on Long-Term Market Sustainability
Taiwan is trying to balance affordability with maintaining a healthy pharmaceutical ecosystem.
Frequent price reductions can discourage market participation, something regulators appear to be addressing now.
What This Means for Global Pharma Companies
For global manufacturers, these reforms create both opportunities and challenges.
Opportunities:
- Faster market access
- Improved reimbursement predictability
- Better opportunities for innovative drugs
- More stable pricing environment
Challenges:
- Changing reimbursement frameworks
- Stronger pricing negotiations
- Need for local market expertise
- Supply continuity expectations
Companies entering Taiwan must now think beyond approvals and focus on reimbursement strategy as well.
Why Local Regulatory & Market Access Support Matters
Taiwan’s pricing and reimbursement environment can be difficult for companies unfamiliar with local requirements.
A strong Regulatory partner can help with:
- Pricing strategy
- Reimbursement submissions
- Regulatory approvals
- Lifecycle maintenance
- Market access planning
As Taiwan continues evolving its healthcare policies, local expertise can help companies stay competitive.
Planning to expand into Taiwan? Talk to Freyr experts today.
